AKT News

News

Capivasertib Plus Palbociclib and Fulvestrant Demonstrated Safety, Tolerability Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

01/16/2024

Stephanie Holland ;

Updated phase 1b results from the CAPItello-292 study demonstrated that capivasertib plus palbociclib and fulvestrant was safe and tolerable among heavily pre-treated patients with HR-positive, HER2-negative advanced breast cancer.

Updated phase 1b results from...

01/16/2024

Oncology

News

Addition of Capivasertib to Fulvestrant Improved PFS Across All Key AKT Pathway Alterations Among Patients With HR-Positive, HER2-Negative Breast Cancer

12/19/2023

Allison Casey ;

According to an exploratory analysis of the CAPItello-291 trial, the benefit to progression-free survival seen with the addition of capivasertib to fulvestrant was consistent among patients with alterations in all 3 key genes within the AKT...

According to an exploratory...

12/19/2023

Oncology

News

Capivasertib Plus Fulvestrant Approved for Patients With HR-Positive, HER2-Negative Breast Cancer

11/20/2023

Stephanie Holland ;

Based on results from the phase 2 CAPItello-291 study, the FDA has approved capivasertib plus fulvestrant for patients with previously treated HR-positive, HER2-negative, locally advanced or metastatic breast cancer harboring one or more...

Based on results from the phase...

11/20/2023

Oncology

News

Capivasertib Plus Fulvestrant Prolonged PFS in HR-Positive, HER2-Negative Advanced Breast Cancer

08/02/2023

Stephanie Holland ;

Data from a phase 3 trial found that adding capivasertib to fulvestrant significantly prolonged progression-free survival among patients with HR-positive, HER2-negative advanced breast cancer, compared to fulvestrant alone.

Data from a phase 3 trial found...

08/02/2023

Oncology

News

Fulvestrant Plus Capivasertib Extends Survival in ER-Positive, HER2-Negative Breast Cancer

07/05/2022

Derek Cowsert ;

Study findings suggest fulvestrant plus capivasertib yielded consistently longer OS and PFS among patients with ER-positive, HER2-negative advanced breast cancer.

Study findings suggest...

07/05/2022

Oncology

News

No Benefit Adding Ipatasertib to First-Line Paclitaxel for PIK3CA-Altered TNBC

11/27/2021

IPATunity130 trial data showed that adding ipatasertib to paclitaxel did not improve PFS in patients with PIK3CA/AKT1/PTEN-altered TNBC.

IPATunity130 trial data showed...

11/27/2021

Oncology

News

Capivasertib Plus Paclitaxel Superior to Paclitaxel Alone for Metastatic TNBC

10/19/2020

Capivasertib in combination with paclitaxel yielded longer PFS and OS in patients with metastatic TNBC, particularly those with PIK3CA/AKT1/PTEN-altered tumors.

Capivasertib in combination with...

10/19/2020

Oncology

News

Fulvestrant–Capivasertib Combo Significantly Prolongs Survival in ER-Positive Breast Cancer

02/14/2020

Adding capivasertib to fulvestrant therapy significantly extends PFS over placebo plus fulvestrant in patients with metastatic, ER-positive breast cancer.

Adding capivasertib to...

02/14/2020

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology